Dual-Tracer Theranostic PET

Inclusion Criteria: * adults aged 18 years or greater. * willing and able to sign a written informed consent and HIPAA authorization in accordance with local and institutional guidelines. * presence of at least 1 measurable lesion ≥ 1 cm in size. * willing to have their clinical records reviewed for at least 24 months after enrollment. * willing to lie flat on their back in the PET/CT scanner for up to one hour to allow for the imaging data to be obtained. * willing to undergo two separate PET/CT exams on different days within 2 weeks of each other. * female participants who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans. The serum pregnancy test must be performed within 48 hours prior to research PET imaging. A negative test will be necessary for such patients to undergo research PET imaging. This only applies to Arms 1 and 2, since only males will be included in Arm 3 (only males can get prostate cancer). * Arms 1 and 2 only: known or suspected somatostatin receptor-positive neuroendocrine tumor (NET) who could be considered for clinical use of DOTATATE PET/CT imaging under the approved indications for use of this radiopharmaceutical according to published appropriate use criteria. These indications include initial staging after the histologic diagnosis of NET, evaluation of an unknown primary; evaluation of a mass suggestive of NET not amenable to endoscopic or percutaneou…